MCDC

The Access to Advanced Health Institute Receives up to $12.7 Million to Develop Novel NanoAlum Adjuvant Formulation for Better Protection Against Tuberculosis and Pandemic Influenza

Retrieved on: 
Thursday, March 7, 2024
COVID-19, Research, Clinical Trials, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Hepatitis A, Senior, Infectious Disease Research Institute, Immune system, Toxicology, Doctor of Philosophy, Medicine, Multimedia, TLR, Government, Infection, Access, Defense, RTS, Vaccine, Notifiable disease, Shingles, Malaria, Unitary state, Respiratory syncytial virus, Formulation, Fungus, MPH, MCDC, Disease, Tuberculosis, OTA, Parasitism, HIV, Cancer

View the full release here: https://www.businesswire.com/news/home/20240307661956/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307661956/en/
    This five-year prototype project will support AAHI’s development and optimization of “NanoAlum” – a novel nanoparticle adjuvant formulation, made from aluminum salts (“alum”).
  • Alum-adjuvanted vaccines have been less effective against diseases such as tuberculosis and influenza, which are more complex to target and can be challenging to manufacture because they require special sterilization methods.
  • AAHI’s NanoAlum formulation changes the size, shape, and charge of alum particles to enhance specific immune responses for better vaccine protection against complex diseases.
  • AAHI’s prototype project for MCDC will pair the combined 3M-052 and NanoAlum formulation with tuberculosis and pandemic influenza vaccine antigens.

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

Retrieved on: 
Thursday, February 15, 2024
DNA, Saponin, GMD, Toxicity, Enzyme, Ginkgo Bioworks, Medicine, SVP, Partnership, Animal, Vaccine, ADC, Refrigeration, Vaccination, Shingles, Malaria, COVID-19, Respiratory syncytial virus, Chemical substance, Saccharomyces cerevisiae, CBD, DTRA, Protein, MCDC, QS-21, Plague, Ginkgo

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Key Points: 
  • Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
  • Currently, only a handful of adjuvants are available for human use in licensed vaccines.
  • Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae.
  • Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.

First Human Clinical Study to Assess U.S. Department of Defense DNA Vaccine Candidate against Venezuelan Equine Encephalitis Delivered with PharmaJet Precision Delivery Systems.

Retrieved on: 
Thursday, November 16, 2023
Medical Devices, Medical Supplies, Homeland Security, Public Policy, Government, Clinical Trials, Biotechnology, White House, Federal Government, Health, Pharmaceutical, Stratis, ID, Institutional review board, MCDC, VEE, DNA, IRB, Alphavirus, Clinical trial, Mortality, Epidemic, DTRA, FDA, Venezuelan equine encephalitis virus, NHP, USAMRIID, Use, Injection, Unitary state, Infection, Vaccine

The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.

Key Points: 
  • The Phase 1 study, sponsored by PharmaJet, aims to identify the optimal dose, vaccination schedule and delivery system most suitable for use in subsequent broader clinical evaluations of the VEE DNA vaccine candidate.
  • The VEE DNA vaccine candidate is being evaluated as part of a multi-year agreement between PharmaJet and the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA) .
  • The study, in collaboration with USAMRIID, aims to further advance the clinical assessment of the vaccine with the PharmaJet Precision Delivery Systems: Tropis Intradermal (ID) and Stratis Intramuscular (IM).
  • The PharmaJet Precision Delivery Systems are optimized for field use and have also shown immunogenicity levels higher than with needle-syringe.

EQS-News: Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program

Retrieved on: 
Wednesday, July 5, 2023
Linda, Immortalised cell line, ASPR, Office of Inspector General, U.S. Department of Health and Human Services, Plague, Medicine, Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical and Biological Defense, U.S. Department of Defense Strategy for Operating in Cyberspace, Just, HHS, United States Department of Defense, OTA, AND, JUST, De novo, Orthopoxvirus, Administration, DOD, Development, MCDC, Administration for Strategic Preparedness and Response, Mab, ISIN, Frankfurt Stock Exchange, BARDA, Radiation, EVO, MDAX, Vaccine, Fine chemical, Pharmaceutical industry, Defense, Hook effect, Chemical substance

Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program

Key Points: 
  • Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
    The issuer is solely responsible for the content of this announcement.
  • Under the contract, Just – Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase I first-in human (“FIH”) clinical trials.
  • Dr Linda Zuckerman, Executive Vice President Global Head Biotherapeutics at Just – Evotec Biologics commented: “It is an honor to expand our collaboration with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (“JPEO-CBRND”) with this second target program effort to support the DOD’s Accelerated Antibodies Program.
  • A first contract under the Accelerated Antibodies Program for the development of mAbs against plague was awarded to Just – Evotec Biologics in September of 2022.

EverGlade Consulting Founder, Eric Jia-Sobota, Announces Promotions, New Hires and 20% Growth in Q12023

Retrieved on: 
Tuesday, March 7, 2023
Forecasting, NSF, Clemson University, Financial management, Growth, Immunology, Small business, Accounting, Management consulting, Consultant, BARDA, Microbiology, DARPA, MTEC, Vanderbilt University, NIAID, MCDC, Management

CHARLESTON, S.C., March 7, 2023 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a national consulting firm, announces key promotions and new hires while achieving 20% growth in the first quarter of 2023.

Key Points: 
  • CHARLESTON, S.C., March 7, 2023 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a national consulting firm, announces key promotions and new hires while achieving 20% growth in the first quarter of 2023.
  • "These promotions are a direct reflection of the hard work and dedication our employees exhibit towards our team and our clients every day, said EverGlade Consulting President, Jerry Jia-Sobota.
  • In addition to promotions, EverGlade continues to grow with several key hires.
  • "I am excited that EverGlade continues to grow and prosper," said EverGlade Founder Eric Jia-Sobota.

Red River Bank and FHLB Dallas Award $24K to Shreveport Nonprofits

Retrieved on: 
Friday, October 21, 2022
Other Consumer, Business, Women, Generation Z, Seniors, Generation X, Other Philanthropy, Men, Finance, Banking, Fund Raising, Consumer, Professional Services, Philanthropy, LGBTQ+, DEI (Diversity, Equity and Inclusion), Millennials, Lifestyle, Federal Home Loan Banks, Congress, Housing, CRA, Education, Parent, Lake, FHLB, District, MSA, Multimedia, Investment, Partnership, PGP, Nasdaq, Economic development, Neighbourly (community investment platform), Riverbank, MCDC, Baton Rouge, Louisiana, Bank, Public relations, Management, Online gambling, Lafayette, Points of the compass

Red River Bank and the Federal Home Loan Bank of Dallas (FHLB Dallas) awarded $24,000 in Partnership Grant Program (PGP) funding to two community organizations in Louisiana during a ceremonial check presentation today.

Key Points: 
  • Red River Bank and the Federal Home Loan Bank of Dallas (FHLB Dallas) awarded $24,000 in Partnership Grant Program (PGP) funding to two community organizations in Louisiana during a ceremonial check presentation today.
  • View the full release here: https://www.businesswire.com/news/home/20221021005494/en/
    Representatives from Red River Bank and the Federal Home Loan Bank of Dallas joined to award $24,000 to two local workforce development nonprofits in Shreveport and Bossier City, Louisiana.
  • We sincerely appreciate Red River Bank and FHLB Dallas for their support in helping to further our mission.
  • Red River Bank is a subsidiary of Red River Bancshares, Inc., which trades under the trading symbol RRBI on the Nasdaq Global Select Market.

Eight Winners of the 2022 Medical Innovation Challenge Announced at Defense TechConnect Innovation Summit & Expo

Retrieved on: 
Thursday, September 29, 2022
Hospital, University, Convention center, Global Innovation through Science and Technology initiative, Therapy, MTEC, Department, Saliva, Brain, Acquisition, Compliance, Centre for the Advancement of Sustainable Medical Innovation, Partnership, Industry, Stroke, Government, Infection, Mental health, Intelligence, ATI, Defense, Student, Technology, LAUNCH (Innovation Challenge), ANSER, Solution, Extracellular matrix, MCDC, Defence Analytical Services and Advice, Anxiety, Ultimate tensile strength, Atrial fibrillation, DTC, Music, Research, U.S. Department of Defense Strategy for Operating in Cyberspace, SHIC, Bone fracture, Depression, Medical imaging, Mobile phone, Pharmaceutical industry, Security (finance), Mass

WASHINGTON,  Sept. 29, 2022  /PRNewswire-PRWeb/ -- Advanced Technology International (ATI), TechConnect and four medtech industry consortia today announced the seven winners of the 2022 Medical Innovation Challenge as well as an eighth winner from innovations created by students. Selected from a field of 25 finalists, winners were presented a total $250,000 in cash prizes at the Defense TechConnect (DTC) Innovation Summit & Expo, the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.

Key Points: 
  • WASHINGTON, Sept. 29, 2022 /PRNewswire-PRWeb/ -- Advanced Technology International (ATI), TechConnect and four medtech industry consortia today announced the seven winners of the 2022 Medical Innovation Challenge as well as an eighth winner from innovations created by students.
  • Selected from a field of 25 finalists, winners were presented a total $250,000 in cash prizes at the Defense TechConnect (DTC) Innovation Summit & Expo , the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.
  • The Defense TechConnect (DTC) Innovation Summit & Expo is the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.
  • DTC is proud to be one of the original innovation hubs to support the Department of Defense and its missions.

Defense TechConnect 2022 Innovation Summit & Expo to Feature Senior Leaders from DoD, Federal Agencies, Industry Consortia and the Private Sector

Retrieved on: 
Thursday, September 22, 2022
Senior advisor, Consortium, Industry, Government, Technology, Air force, Department of Defence, Assistant, Integration, Mohawk Innovative Technology, Climate, Marine Corps Combat Development Command, Atmosphere of Earth, ANSER, Innovation, University, Convention center, Resilience, ADC, VLC, Commanding officer, LAUNCH (Innovation Challenge), Mass, Small business, DTC, Defense Department Advisory Committee on Women in the Services, Small Business Administration, United States Air Force, National Harbor, Maryland, NSF, Create, United States Department of Defense, ATI, Defense, EDA, National, Private sector, Investment, MCDC, National Security Council, Management, Security (finance), Entrepreneurship

WASHINGTON, Sept. 22, 2022 /PRNewswire-PRWeb/ -- The Defense TechConnect (DTC) 2022 Innovation Summit & Expo, the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements, today announced its final lineup of keynote addresses and panel discussions. One of the most well-attended defense innovation conferences of the year, DTC will be held on Sept. 27-29, 2022, at Gaylord National Hotel & Convention Center, 201 Waterfront St., National Harbor, Md.

Key Points: 
  • To be held Sept. 27-29, 2022, Defense TechConnect's keynote addresses and panel discussions will address the state of innovation collaboration within the Defense Department and its new model for federal partnerships with the private sector.
  • WASHINGTON, Sept. 22, 2022 /PRNewswire-PRWeb/ -- The Defense TechConnect (DTC) 2022 Innovation Summit & Expo , the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements, today announced its final lineup of keynote addresses and panel discussions.
  • One of the most well-attended defense innovation conferences of the year, DTC will be held on Sept. 27-29, 2022, at Gaylord National Hotel & Convention Center, 201 Waterfront St., National Harbor, Md.
  • The six DTC Innovation Challenges and their dates are:

Defense TechConnect 2022 Innovation Summit & Expo to Feature Six Innovation Challenges for Accelerating Cutting-edge Technologies to Support the National Defense Strategy

Retrieved on: 
Thursday, September 8, 2022
National Science Foundation, MTEC, Technology, Science, Research, Convention center, Consortium, National Harbor, Maryland, DTC, National Security Innovation Network, ATI, ANSER, University, Global Innovation through Science and Technology initiative, Government, Engineering statistics, Department, Intelligence, U.S. Department of Defense Strategy for Operating in Cyberspace, Defense, Create, Industry, Defence Analytical Services and Advice, Partnership, National Center for Telehealth & Technology, Mass, VLC, Investment, Acceleration, SBIR, Privacy, Homeland, RISE, ADC, Acquisition, HSTC, Aviation, AI, Immersion, Artificiality, NSC, MCDC, LAUNCH (Innovation Challenge), Therapy, SHIC, Video game, Management, Security (finance), Pharmaceutical industry, Medical device, MD

WASHINGTON, Sept. 8, 2022   /PRNewswire-PRWeb/ -- 

Key Points: 
  • To be held Sept. 27-29, 2022, the Defense TechConnect 2022 Innovation Summit & Expo's six Innovation Challenges will feature "Shark Tank"-style pitches by startups, universities and national labs competing for more than $500,000 in total prizes.
  • The Defense TechConnect (DTC) 2022 Innovation Summit & Expo , the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements, will convene on Sept. 27-29, 2022, at Gaylord National Hotel & Convention Center, 201 Waterfront St., National Harbor, MD.
  • DTC also will feature its own innovation spotlights program featuring universities and startups presenting over the three-day program."
  • The Defense TechConnect (DTC) Innovation Summit & Expo is the nation's largest annual gathering of non-traditional, dual-use emerging technologies aligned with government priority requirements.

ATI Augments Medical Innovation Challenge Prize, Stands Up $250,000 Non-Dilutive Award for Innovators

Retrieved on: 
Thursday, April 28, 2022
Medicine, Challenge, Defence Analytical Services and Advice, Consortium, Commercialization, Technology, Partnership, Defense, Therapy, Centre for the Advancement of Sustainable Medical Innovation, ANSER, SHIC, Multimedia, View, Research, ATI, Industry, Government, Mass, Global Innovation through Science and Technology initiative, MTEC, MCDC, Pharmaceutical industry, Renewable energy

"As we emerge from a global pandemic, the timing has never been better to accelerate medical innovation.

Key Points: 
  • "As we emerge from a global pandemic, the timing has never been better to accelerate medical innovation.
  • The Medical Innovation Challenge seeks to harness the power of groundbreaking medical solutions, establish meaningful paths forward for top innovators, and ultimately improve outcomes for the nation," said Matthew Laudon, Vice President TechConnect Division, ATI.
  • Qualified applicants receive a 12-month membership opportunity to the Medical CBRN Defense Consortium (MCDC), Countering Weapons of Mass Destruction (CWMD) Consortium, Medical Technology Enterprise Consortium (MTEC), and Senior Healthcare Innovation Consortium (SHIC).
  • "The Medical Technology Enterprise Consortium (MTEC) eagerly supports the Medical Innovation Challenge in attracting the best and brightest medical innovators to pitch and connect their technology with leading corporate, investment, and federal sponsors," said Rick Satcher, Director of Commercialization for MTEC.